瑞倍適(RYBELSUS)即將上市！

目前當紅炸子雞胰妥讚Semaglutide (Ozempic. ®. ) ，不論在血糖跟體重控制都是Glucagon-like peptide-1(GLP1 RA)腸泌素類別的佼佼者。一週注射一次，還是會讓有些人望之卻步。

但是好消息來了！口服版本的胰妥讚(ozempic)，口服GLP-1降糖藥，也就是瑞倍適(RYBELSUS)。這個月舉行上市前相關活動，估計在近期就會發表上市。

在第二型糖尿病人身上，關於體重減少(減重)的部分

1.對比生活飲食控制(26週)

瑞倍適RYBELSUS (14mg)減少3.7公斤，瑞倍適RYBELSUS (7mg)減少2.3公斤，對照組減少1.4公斤

2.對比Liraglutide 1.8mg (52週) (台灣同成份商品有Victoza 胰妥善注射液、Saxenda 善纖達減重筆)

瑞倍適RYBELSUS (14mg)減少4.3公斤，瑞倍適RYBELSUS (7mg)減少3公斤，對照組減少1公斤

3.對比Sitagliptin 100mg (78週) (台灣商品名為佳糖維Januvia，屬於DPP4抑制劑)

瑞倍適RYBELSUS (14mg)減少3.2公斤，瑞倍適RYBELSUS (7mg)減少2.7公斤，對照組減少1公斤

4. 對比Empagliflozin 25mg (52週) (台灣商品名為恩排糖Jardiance，俗稱排糖藥，屬於SGLT2抑制劑)

瑞倍適RYBELSUS (14mg)減少3.8公斤，對照組減少3.6公斤

REFERENCE:

1.Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.

2.Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

3.Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

4.Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

5.Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial